Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.36 |
| ▸ | HTR1A | P08908 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16088018 | 0.83 | KDM4E (0.37) | KDM4E | |
| SCHEMBL16948554 | 0.75 | KDM4E (0.53) | MEN1KMT2AADRB2HTR1AKDM4E | |
| SCHEMBL14980587 | 0.74 | KMT2A (0.47) | MEN1KMT2AADRB2KDM4ECYP1A2 | |
| SCHEMBL20127149 | 0.74 | KDM4E (0.52) | MEN1KMT2AADRB2HTR1AKDM4E | |
| SCHEMBL13007964 | 0.74 | MEN1 (0.39) | MEN1KMT2AADRB2HTR1AKDM4E | |
| SCHEMBL29624902 | 0.74 | KDM4E (0.38) | MEN1KMT2AADRB2HTR1AKDM4E | |
| SCHEMBL8602173 | 0.74 | ADRB2 (0.46) | MEN1KMT2AADRB2HTR1AKDM4E | |
| SCHEMBL14193385 | 0.71 | ADRB2 (0.45) | MEN1KMT2AADRB2KDM4ECYP1A2 | |
| SCHEMBL24864628 | 0.71 | ADRB2 (0.36) | MEN1KMT2AADRB2HTR1AKDM4E | |
| SCHEMBL16944226 | 0.71 | KDM4E (0.44) | MEN1KMT2AADRB2HTR1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9687573-B2 | Compositions and associated methods for radioisotope-binding microparticles | BIOSPHERE MEDICAL, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20140271461-A1 | COMPOSITIONS AND ASSOCIATED METHODS FOR RADIOISOTOPE-BINDING MICROPARTICLES | BIOSPHERE MEDICAL, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271461-A1 | COMPOSITIONS AND ASSOCIATED METHODS FOR RADIOISOTOPE-BINDING MICROPARTICLES | CD47, CD68, MPI | MEN1 138/4885KMT2A 4620/4885ADRB2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.